NPS Pharmaceuticals Names Douglas N. Dobak Vice President of Regulatory Affairs and Drug Safety

    BEDMINSTER, N.J., Oct. 30 /CNW/ -- NPS Pharmaceuticals, Inc. (Nasdaq:  
NPSP) announced today the appointment of Douglas N. Dobak as vice president,
regulatory affairs and drug safety.  Mr. Dobak joins NPS from AstraZeneca
where he served in various senior leadership positions within that company's
global and U.S. regulatory affairs organizations.  His most recent positions
at AstraZeneca were executive director, U.S. regulatory affairs, and global
vice president, regulatory affairs, respiratory and inflammation area.
Previously, he held regulatory affairs positions with Pfizer, Janssen
Pharmaceutical, SmithKline Beecham, DuPont Pharmaceuticals, and Bristol-Myers
    "Doug brings more than thirty years of experience supporting new drug
approvals and product launches for many of the pharmaceutical industry's
leading companies," said Dr. Francois Nader, executive vice president and
chief operating officer of NPS, to whom Mr. Dobak will report.  "His expertise
in regulatory affairs and knowledge of multiple therapeutic areas, including
gastrointestinal disorders, will be invaluable as we work to advance our late-
stage product candidates, GATTEX and PREOS.  In particular, Doug has played
important roles in the approval and launch of Propulsid and Nexium and line
extensions for Prilosec that will be helpful as we continue our work in the
treatment of gastrointestinal disorders with GATTEX."
    About NPS
    NPS Pharmaceuticals is a biopharmaceutical company focused on the
development and commercialization of small molecules and recombinant proteins
as drugs, primarily for the treatment of metabolic, bone and mineral, and
central nervous system disorders. The company has drug candidates in various
stages of clinical development. Additional information is available on the
company's website,
    Note: Statements made in this press release, which are not historical in
nature, constitute forward-looking statements for purposes of the safe harbor
provided by the Private Securities Litigation Reform Act of 1995. These
statements are based on management's current expectations and beliefs and are
subject to a number of factors and uncertainties that could cause actual
results to differ materially from those described in the forward-looking
statements. All information in this press release is as of October 30, 2007
and we undertake no duty to update this information. A more complete
description of these risks can be found in our filings with the Securities and
Exchange Commission, including our Annual Report on Form 10-K for the year-
ended December 31, 2006 and our Quarterly Report on Form 10-Q for the quarter-
ended June 30, 2007.

For further information:

For further information: Brandi Simpson of NPS Pharmaceuticals, Inc., 
+1-908-450-5616 Web Site:

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890